Heberling, who joins the private equity firm from the Abu Dhabi Investment Authority (ADIA), is a seasoned healthcare investor and is expected to enhance BC’s coverage across the continent, in particular in France and Germany.
ADIA brought him on board in 2014 to lead its move into direct deal making and he became its head of healthcare in 2017, leading high-profile investments including Nestlé Skin Health (Galderma) in 2019 and Pharmaceutical Product Development (PPD) in 2017.
Prior to joining ADIA, he spent 12 years at the London office of Cinven, where he played an integral role in its investments in Spire Healthcare, Numericable, MediMedia and Springer Science.
BC Partners chairman Raymond Svider described Heberling as a ‘long-time friend’ of BC Partners, whose investment philosophy was a ‘great cultural fit’.
‘At BC Partners, the strength of our talent has always been key to delivering value to our portfolio companies and clients. Healthcare is a sector where we see huge potential and we are therefore very excited to have someone of Pascal’s calibre and experience to help us capitalise on these opportunities,’ he added.
Commenting on his appointment, Heberling said: ‘I have been impressed by the firm’s positioning, building on its long history and track record to become a truly dynamic, modern and diversified investor in private markets. BC Partners’ culture is one that is collegial and humble, with an emphasis on relationships, making the firm a partner of choice for founders, entrepreneurs and corporate sellers. I very much look forward to joining the partnership later this year and working with my new colleagues to continue growing the business.’